Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Self-Administered Gerocognitive Examination (SAGE) for the Early Detection of Cognitive Impairment at Primary Care Provider (PCP) Visits
Aging, Dementia, and Behavioral Neurology
Aging and Dementia Posters (7:00 AM-5:00 PM)
060

To compare PCP visits with and without using SAGE to determine differences in diagnoses, treatment, and management of new cognitive disorders.

50%-75% of dementia cases are undiagnosed, untreated, and unmanaged. Cognitive assessments are time consuming and difficult to incorporate into time-limited PCP visits. SAGE is a cognitive assessment not requiring administrator time.

Subjects aged 65-89 without diagnosed cognitive disorders completing a non-acute office visit were enrolled. Two physically separate PCP offices conducted the visits as they normally would for 100 consecutive subjects each. One office used SAGE in an additional 100 subjects and asked available informants about cognitive changes over the previous year. Chart reviews were conducted 60 days later. One-way analysis of variance and Fisher exact tests were used to compare the groups and outcomes.

There were no differences in age, race, or gender between intervention (n=100) and control (n=200) subgroups. When SAGE was utilized, the PCP documented detection of new cognitive conditions/concerns six times (9% versus 1.5%) as often (p=0.003). The intervention group detection rate was nearly 4-fold for those with cognitively impaired SAGE scores (p=0.034). Individuals having both impaired SAGE and informant concerns were 15-fold as likely to have new cognitive conditions/concerns documented (p=0.0007). In a sample of providers using SAGE, 86% would recommend SAGE to colleagues but approximately 25% felt it took up too much time during routine visits. Providers recommended that SAGE may be better utilized if given outside of exam rooms and at Annual Wellness Visits to prevent workflow disruption and allow for discussion time.

SAGE was easily incorporated into PCP visits and resulted in significantly increased awareness of new cognitive conditions/concerns leading to new diagnoses, treatment, or management changes. Detection rate increased 15-fold for those with impaired SAGE scores combined with informant reports of significant cognitive declines over a year.

Authors/Disclosures
Douglas W. Scharre, MD, FÂé¶¹´«Ã½Ó³»­ (Ohio State University)
PRESENTER
Dr. Scharre has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for BrainTest, Inc. Dr. Scharre has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Otsuka. Dr. Scharre has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai. Dr. Scharre has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Scharre has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Eisai. Dr. Scharre has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Eli Lilly. The institution of Dr. Scharre has received research support from InSightec. The institution of Dr. Scharre has received research support from Alzheimer's Therapeutic Research Institute (ATRI). The institution of Dr. Scharre has received research support from Eisai. The institution of Dr. Scharre has received research support from vTv Therapeutics. The institution of Dr. Scharre has received research support from National Institute of Health. The institution of Dr. Scharre has received research support from Eli Lilly. The institution of Dr. Scharre has received research support from Biogen. The institution of Dr. Scharre has received research support from Roche. The institution of Dr. Scharre has received research support from Percision Medicine. The institution of Dr. Scharre has received research support from Premier Research Group. The institution of Dr. Scharre has received research support from Genetch. The institution of Dr. Scharre has received research support from Avanir. The institution of Dr. Scharre has received research support from Cerevel Therapeutics. The institution of Dr. Scharre has received research support from Janssen. The institution of Dr. Scharre has received research support from Cassava. The institution of Dr. Scharre has received research support from UniQure. The institution of Dr. Scharre has received research support from Cognition Therapeutics. The institution of Dr. Scharre has received research support from Cognitive Research Corporation. The institution of Dr. Scharre has received research support from EIP. The institution of Dr. Scharre has received research support from Cognito. Dr. Scharre has received intellectual property interests from a discovery or technology relating to health care. Dr. Scharre has received intellectual property interests from a discovery or technology relating to health care.
Nicole Vrettos Ms. Vrettos has nothing to disclose.
No disclosure on file